PLRZ | tickerfilter.com

Fundamental analysis

Profitability 0%

Dept financing 0%

Liquidity 0%

Performance 0%

Performance

5 Days

6.40%

1 Month

-18.60%

3 Months

-27.20%

6 Months

921.05%

1 Year

3,427.27%

2 Year

1,019.23%

Key data

Stock price

$11.64

P/E Ratio

N/A

DAY RANGE

$11.17 - $11.98

EPS

N/A

52 WEEK RANGE

$0.00 - $18.20

52 WEEK CHANGE

$3,537.50

MARKET CAP

0.000

YIELD

N/A

SHARES OUTSTANDING

0.000

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

1.41

PUBLIC FLOAT

N/A

AVERAGE 10 VOLUME

$52,668

AVERAGE 30 VOLUME

$39,712

Company detail

CEO: Tomer Izraeli
Region: US
Website: polyrizon-biotech.com
Employees: 0
IPO year: 2024

Issue type:
Market: NASDAQ
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

We are a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. We are an Israeli corporation, incorporated in January 2005. Our principal executive offices are located at 5 Ha-Tidhar Street, Raanana, 4366507, Israel.

PLRZ - Polyrizon Ltd.